263 related articles for article (PubMed ID: 9094607)
1. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.
Gubareva LV; Robinson MJ; Bethell RC; Webster RG
J Virol; 1997 May; 71(5):3385-90. PubMed ID: 9094607
[TBL] [Abstract][Full Text] [Related]
2. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en.
Gubareva LV; Bethell R; Hart GJ; Murti KG; Penn CR; Webster RG
J Virol; 1996 Mar; 70(3):1818-27. PubMed ID: 8627706
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.
Staschke KA; Colacino JM; Baxter AJ; Air GM; Bansal A; Hornback WJ; Munroe JE; Laver WG
Virology; 1995 Dec; 214(2):642-6. PubMed ID: 8553569
[TBL] [Abstract][Full Text] [Related]
4. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.
McKimm-Breschkin JL; Sahasrabudhe A; Blick TJ; McDonald M; Colman PM; Hart GJ; Bethell RC; Varghese JN
J Virol; 1998 Mar; 72(3):2456-62. PubMed ID: 9499107
[TBL] [Abstract][Full Text] [Related]
5. Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
Goto H; Bethell RC; Kawaoka Y
Virology; 1997 Nov; 238(2):265-72. PubMed ID: 9400599
[TBL] [Abstract][Full Text] [Related]
6. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en.
Blick TJ; Tiong T; Sahasrabudhe A; Varghese JN; Colman PM; Hart GJ; Bethell RC; McKimm-Breschkin JL
Virology; 1995 Dec; 214(2):475-84. PubMed ID: 8553549
[TBL] [Abstract][Full Text] [Related]
7. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture.
Colacino JM; Laver WG; Air GM
J Infect Dis; 1997 Aug; 176 Suppl 1():S66-8. PubMed ID: 9240698
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
9. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.
Gubareva LV; Webster RG; Hayden FG
Antiviral Res; 2002 Jan; 53(1):47-61. PubMed ID: 11684315
[TBL] [Abstract][Full Text] [Related]
10. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.
Tai CY; Escarpe PA; Sidwell RW; Williams MA; Lew W; Wu H; Kim CU; Mendel DB
Antimicrob Agents Chemother; 1998 Dec; 42(12):3234-41. PubMed ID: 9835519
[TBL] [Abstract][Full Text] [Related]
11. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.
McKimm-Breschkin JL; Blick TJ; Sahasrabudhe A; Tiong T; Marshall D; Hart GJ; Bethell RC; Penn CR
Antimicrob Agents Chemother; 1996 Jan; 40(1):40-6. PubMed ID: 8787876
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
Gubareva LV; Penn CR; Webster RG
Virology; 1995 Oct; 212(2):323-30. PubMed ID: 7571401
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Sidwell RW; Huffman JH; Barnard DL; Bailey KW; Wong MH; Morrison A; Syndergaard T; Kim CU
Antiviral Res; 1998 Feb; 37(2):107-20. PubMed ID: 9588843
[TBL] [Abstract][Full Text] [Related]
14. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en.
Blick TJ; Sahasrabudhe A; McDonald M; Owens IJ; Morley PJ; Fenton RJ; McKimm-Breschkin JL
Virology; 1998 Jun; 246(1):95-103. PubMed ID: 9656997
[TBL] [Abstract][Full Text] [Related]
15. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro.
Woods JM; Bethell RC; Coates JA; Healy N; Hiscox SA; Pearson BA; Ryan DM; Ticehurst J; Tilling J; Walcott SM
Antimicrob Agents Chemother; 1993 Jul; 37(7):1473-9. PubMed ID: 8363379
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
McSharry JJ; McDonough AC; Olson BA; Drusano GL
Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
[TBL] [Abstract][Full Text] [Related]
17. Sialidase activity of influenza A virus in an endocytic pathway enhances viral replication.
Suzuki T; Takahashi T; Guo CT; Hidari KI; Miyamoto D; Goto H; Kawaoka Y; Suzuki Y
J Virol; 2005 Sep; 79(18):11705-15. PubMed ID: 16140748
[TBL] [Abstract][Full Text] [Related]
18. A single sequence change destabilizes the influenza virus neuraminidase tetramer.
Colacino JM; Chirgadze NY; Garman E; Murti KG; Loncharich RJ; Baxter AJ; Staschke KA; Laver WG
Virology; 1997 Sep; 236(1):66-75. PubMed ID: 9299618
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.
Masuda T; Yoshida S; Arai M; Kaneko S; Yamashita M; Honda T
Chem Pharm Bull (Tokyo); 2003 Dec; 51(12):1386-98. PubMed ID: 14646315
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.
Hayden FG; Treanor JJ; Betts RF; Lobo M; Esinhart JD; Hussey EK
JAMA; 1996 Jan 24-31; 275(4):295-9. PubMed ID: 8544269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
